No abstract

A contemporary and expanding area of toxicology research is nanotoxicology. It focuses on evaluating the toxicological characteristics of nanoparticles (NPs) in order to determine whether and how much of a risk they pose to society or the environment. Fundamental characteristics of nanoparticles (consisting of shape, size, surface charge, surface area, solubility/dissolution, coating, and crystal structure), in addition to coincidental aspects (like climate, pH, salinity, ionic potency, and organic material), generally impact NP attitude, circumstance, and movement, and basically toxicity. The processes underpinning nanomaterials' (NMs) toxicity have recently been intensively researched. One such mechanism is the toxicity of reactive oxygen species (ROS). Excessive production of ROS causes oxidative stress, which causes cells to lose their capacity to sustain normal redox-regulated processes. This review consists of details referring to the physical and chemical characteristics of nanomaterials and their properties for convenient toxicological assessment, disclosure, and coincidental transport, fate, and genotoxic effects.

Cancer, one of the leading causes of death worldwide, has been the subject of extensive study by many researchers. Cancer is affected by both genetic and immune system factors in the human body. The gut microbiota plays an important role in the body's capacity to maintain homeostasis. Because of their beneficial effects on human health and their ability to successfully prevent and treat various chronic diseases, such as cancer, probiotics are becoming increasingly important in medicine. A wealth of research has shown that probiotic consumption can significantly helpful in cancer prevention and treatment. The goal of this review is to provide a thorough overview of the research on the function of probiotic bacteria in the prevention and treatment of gastrointestinal cancers.

Pemetrexed (PMT) is a multi-target antifolate that has been confirmed for the treatment of lung cancer. It has significantly boosted the survival rate of patients with non-squamous non-small-cell lung cancer. Multiple Phase II clinical trials have demonstrated that pemetrexed is an effective monotherapy for a range of solid tumors, including colorectal, breast, neck, and head malignancies. Methods for consolidating pemetrexed with other chemotherapeutics and novel molecularly targeted drugs are currently under investigation. Pemetrexed is currently recommended for first-line dose management with platinum chemotherapies, second-line monotherapy drugs, and, in modern chemotherapy protocols, as continuation therapy following first-line therapy. Vitamin B12 (VB12) and folic acid (FA) supplements can aid to minimize the cytotoxicity of pemetrexed. FA/VB12 has been suggested to have an antagonistic effect on pemetrexed's efficacy. Patients who accept FA/VB12 have a higher tolerance for PMT and a longer lifespan. In this study, the pharmacodynamics, pharmacokinetics, and toxicity of pemetrexed were studied, as well as the implications of FA/VB12 as a co-medication with pemetrexed-based chemotherapy.